Related Experiment Video
Updated: Sep 28, 2026

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
Published on: May 27, 2016
Transcription initiation sites and promoter structure of the human TRAIL-R3 gene
Carmen Ruiz de Almodóvar1, Abelardo López-Rivas, Juan Miguel Redondo
1Instituto de Parasitología y Biomedicina, CSIC, calle Ventanilla 11, Granada, Spain.
Abstract:
TRAIL-R3 is a decoy receptor for TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), a member of the tumor necrosis factor ligand family. In several cell types decoy receptors inhibit TRAIL-induced apoptosis by binding TRAIL and preventing its binding to TRAIL pro-apoptotic receptors. Here we report the cloning of the promoter region of human TRAIL-R3 and the mapping of the transcriptional start sites. This gene contains a consensus TATA box and the minimal promoter lies within the first 33 nucleotides upstream of the transcription start site. Transient transfection assays of luciferase reporter plasmids demonstrate that human TRAIL-R3 promoter can be induced in doxorubicin-treated MCF-7 cells in a p53-independent manner.
Insights
Researchers cloned the human TRAIL-R3 decoy receptor promoter, identifying key regulatory elements. The TRAIL-R3 promoter is inducible by doxorubicin in MCF-7 cells, independent of p53 signaling.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- TRAIL-R3 (tumor necrosis factor-related apoptosis-inducing ligand receptor 3) functions as a decoy receptor, inhibiting TRAIL-induced apoptosis.
- Decoy receptors bind TRAIL, preventing its interaction with pro-apoptotic receptors and thus modulating cell death pathways.
Purpose of the Study:
- To clone and characterize the promoter region of the human TRAIL-R3 gene.
- To identify the transcriptional start sites and minimal promoter elements of human TRAIL-R3.
- To investigate the regulation of the TRAIL-R3 promoter in response to doxorubicin treatment.
Main Methods:
- Cloning of the human TRAIL-R3 promoter region.
- Mapping of transcriptional start sites.
- Transient transfection assays using luciferase reporter plasmids in MCF-7 cells.
Main Results:
- The human TRAIL-R3 gene promoter contains a consensus TATA box.
- The minimal promoter region is located within the first 33 nucleotides upstream of the transcription start site.
- Doxorubicin treatment induced the human TRAIL-R3 promoter in MCF-7 cells in a p53-independent manner.
Conclusions:
- The study successfully cloned and characterized the human TRAIL-R3 promoter, revealing its core regulatory elements.
- The findings demonstrate p53-independent induction of the TRAIL-R3 promoter by doxorubicin, suggesting novel regulatory mechanisms in cancer cells.
More Related Videos
Related Concept Videos
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...
Bacterial Transcription
Transcription can be divided into three main stages, each involving distinct DNA sequences to guide the polymerase. These are:
Leaky Scanning
General Transcription Factors

